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In the VIKING study a 50 mg once daily regimen of the
next generation HIV integrase inhibitor (INI) S/
GSK1349572 (572) exhibited promising antiviral activity
in an initial cohort (Cohort I) of treatment-experienced
subjects with documented raltegravir (RAL) resistance.
The purpose of this work was to evaluate via simulation
techniques whether improved virologic responses could
be achieved with higher doses in a second cohort
(Cohort II) by utilizing pharmacokinetic (PK) and phar-
macodynamic (PD) models derived using Cohort I data.
I n t e r i mP Kd a t af r o mV I K I N GC o h o r tIw e r ec o m -
bined with data from Phase 1 and 2a studies in healthy
and HIV+, INI-naïve subjects, respectively; data were
analyzed using a linear two-compartment PK model.
The population PK/PD analysis incorporated log10 HIV-
1 RNA viral load (VL) sampled throughout 10 days of
dosing during the Phase 2a and VIKING studies. The
VL was modelled using an indirect response model in
which the 572 plasma concentrations inhibited HIV-1
RNA production. Final PK and PK/PD models were vali-
dated using the visual predictive check (VPC) technique.
Two sets of simulations were used to predict responder
percentage for dose regimens proposed for Cohort II of
V I K I N G .F i r s t ,c h a n g ef r o mb a s e l i n ei nl o g 10 VL (ΔVL)
at Day 11 was simulated for cohorts of 1000 subjects for
each dose regimen according to different fixed levels of
baseline fold change (FC) in 572 IC50 from wild type
virus. The second set of simulations predicted responder
percentages for clinical RAL-resistant HIV populations
w i t hd i v e r s e5 7 2s u s c e p t i b i l i t i e s .T h ed a t aw e r ew e l l -
described by the respective models. Model parameters
were generally well-determined and VPC plots verified
predictive performance.
Simulations predicted increasing the dose regimen
from 50 mg once daily to 50 mg twice daily would
increase the percentage of patients with FC=8 that
achieved ≥ 1.5 log10 ΔV La tD a y1 1b y~ 2 8 % .S i m i l a r l y ,
improvements in response of ~20% and ~18% were pre-
dicted for patient populations with HIV resistance pro-
files observed in RAL PhIIb and BENCHMRK virologic
failure and VIKING screening populations, respectively.
Our models predict 572 50mg twice daily will appreci-
ably increase Day11 virologic responses in RAL-resistant
subjects, supporting the dosing strategy for the ongoing
Cohort II. 572 shows promise to demonstrate further
the activity in this difficult to treat patient population.
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